Pharmaceuticals

Interleukin-2 (IL-2) Mutein Therapies Industry Growth Insights: Revenue Forecast to 2030

March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the interleukin-2 (il-2) mutein therapies market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Interleukin-2 (IL-2) Mutein Therapies Market reach by 2030 starting from 2026 levels?

The interleukin-2 (il-2) mutein therapies market size has seen swift expansion in recent years. Its value is projected to grow from $0.73 billion in 2025 to $0.84 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.1%. The historical increase can be ascribed to advancements in cytokine engineering techniques, a deeper understanding of immune signaling pathways, initial positive clinical results for modified IL-2 therapies, increased investment in immuno-oncology research, and the rising incidence of immune-mediated diseases.

The interleukin-2 (il-2) mutein therapies market is projected to experience swift expansion in the coming years, reaching a valuation of $1.43 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.4%. This anticipated growth during the forecast period stems from factors such as the broadening of personalized immunotherapy strategies, heightened clinical trial engagement for advanced cytokines, a surging need for more secure immune modulators, increasing regulatory backing for novel biologics, and a rise in collaborations between biotechnology and pharmaceutical firms. Key trends during this period are expected to involve the accelerated creation of receptor-biased il-2 muteins, a heightened emphasis on minimizing cytokine toxicity profiles, the expanding adoption of combination immunotherapy regimens, the extension of precision immune modulation techniques, and augmented clinical pipeline endeavors for both autoimmune and oncological conditions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33185&type=smp

Which Drivers Are Influencing Long-Term Growth In The Interleukin-2 (IL-2) Mutein Therapies Market?

The escalating requirement for targeted immunotherapies is anticipated to boost the expansion of the interleukin-2 (IL-2) mutein therapies market. These specific immunotherapies are treatments developed to modify the immune system, enabling it to selectively target cancer cells while minimizing harm to healthy tissues. The need for these treatments is growing as healthcare professionals and researchers look for safer and more effective alternatives to traditional chemotherapy and radiation therapy, which frequently carry notable toxicity and lack precise targeting. IL-2 mutein therapies advance targeted immunotherapies by employing engineered versions of interleukin-2 that preferentially activate immune effector cells involved in fighting tumors, simultaneously lessening the activation of pathways linked to systemic toxicity. An illustrative example is that in April 2025, the Cancer Research Institute, a US-based non-profit organization, reported that FDA approvals encompassed 17 novel targeted immunotherapy agents in 2024. This expanded the available options for targeted immune-based cancer treatment and broadened the patient population that stands to gain from such therapies. Consequently, the rising demand for targeted immunotherapies is fueling the growth of the interleukin-2 (IL-2) mutein therapies market.

Which Segments Are Driving Activity In The Interleukin-2 (IL-2) Mutein Therapies Market?

The interleukin-2 (il-2) mutein therapies market covered in this report is segmented –

1) By Product Type: Monotherapy; Combination Therapy

2) By Route Of Administration: Intravenous; Subcutaneous; Other Route Of Administrations

3) By Application: Cancer; Autoimmune Diseases; Infectious Diseases; Other Applications

4) By End User: Hospitals; Specialty Clinics; Research Institutes; Other End Users

Subsegments:

1) By Monotherapy: Single Agent Interleukin Two Mutein Therapy; Standalone Cytokine Based Immunotherapy; Targeted Immune Modulation Therapy

2) By Combination Therapy: Interleukin Two Mutein With Immune Checkpoint Inhibitors; Interleukin Two Mutein With Chemotherapy; Interleukin Two Mutein With Targeted Biologic Therapies; Interleukin Two Mutein With Cell Based Therapies

What Upcoming Trends Are Likely To Define The Future Path Of The Interleukin-2 (IL-2) Mutein Therapies Market?

Companies operating within the interleukin-2 (IL-2) mutein therapies market are increasingly prioritizing technological advancements in cytokine-based immunotherapy, notably focusing on selective regulatory T-cell (Treg) activation through engineered IL-2 muteins. This selective activation mechanism involves employing genetically modified IL-2 proteins specifically designed to preferentially stimulate Tregs while simultaneously limiting the activation of effector immune cells. For example, in December 2023, Almirall S.A., a pharmaceutical company based in Spain, commenced the first Phase I clinical study of its engineered IL-2 mutein fusion protein, ALM223, to assess its safety, pharmacokinetics, immunogenicity, and pharmacodynamics in autoimmune diseases. This candidate compound incorporates selective Treg activation, an adapted Fc fusion to enhance molecular stability, and a refined cytokine backbone engineered to optimize immune modulation. While these technological developments demonstrate the promise of IL-2 muteins in achieving targeted immunomodulation and broader applicability in autoimmune conditions, their clinical effectiveness and long-term safety profiles are yet to be definitively established through ongoing and future trials.

Which Key Market Players Are Investing In Expansion And Innovation Within The Interleukin-2 (IL-2) Mutein Therapies Market?

Major companies operating in the interleukin-2 (il-2) mutein therapies market are Merck & Co. Inc., Sanofi S.A., Roche Holding AG, Bristol-Myers Squibb, Amgen Inc., Lonza Group AG, Alkermes plc, BioNTech SE, Xencor Inc., Innovent Biologics Inc., Ascendis Pharma A/S, ShanghAI Junshi Biosciences Co. Ltd., Mural Oncology Inc., ProBioGen AG, Werewolf Therapeutics Ltd., Philogen S.p.A., Cue Biopharma Inc., Medicenna Therapeutics Corp., Bright Peak Therapeutics Inc., Iovance Biotherapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/interleukin-2-il-2-mutein-therapies-market-report

Which Regions Are Poised For Strategic Growth In The Interleukin-2 (IL-2) Mutein Therapies Market?

North America was the largest region in the interleukin 2 (IL-2) mutein therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interleukin-2 (il-2) mutein therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Interleukin-2 (IL-2) Mutein Therapies Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33185&type=smp

Browse Through More Reports Similar to the Global Interleukin-2 (IL-2) Mutein Therapies Market 2026, By The Business Research Company

Artificial Intelligence Ai Studio Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-studio-global-market-report

Ai Content Marketing Market Report 2026

https://www.thebusinessresearchcompany.com/report/ai-content-marketing-global-market-report

Artificial Intelligence Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795